首页 >
法规速递
-
Page: Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular use - Scientific guideline-2026/4/9
2026-04-10查看详情 > -
Page: Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Scientific guideline-2026/4/9
2026-04-10查看详情 > -
Document: Template for sharing EMA documents by Industry to support reliance-2026/4/9
2026-04-10查看详情 > -
Document: Clinical Trial Information System (CTIS) - Sponsor Frequently Asked Questions (FAQ)-2026/4/9
2026-04-10查看详情 > -
Page: PRIME: priority medicines-2026/4/9
2026-04-10查看详情 > -
Document: List of medicines currently in PRIME scheme-2026/4/9
2026-04-10查看详情 > -
Document: List of eligible industry stakeholder organisations-2026/4/9
2026-04-10查看详情 > -
Page: COVID-19 vaccines: key facts-2026/4/8
2026-04-09查看详情 > -
Page: Vaccines: concerns, questions and false claims-2026/4/8
2026-04-09查看详情 > -
Page: Maximum residue limits (MRLs): Questions and answers-2026/4/8
2026-04-09查看详情 >
